Malignant Peritoneal Neoplasm clinical trials
21 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
- A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
- An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
- Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
- Using Aspirin to Improve Immunological Features of Ovarian Tumors
- Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
- Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
- ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors
- BP1001-A in Patients With Advanced or Recurrent Solid Tumors
- Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
- Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
- GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer
- Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors
- Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
- Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
- TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE)
- Feasibility of Addressing Sexual Dysfunction in Women with Breast and Gynecologic Cancers with a Novel Mobile Application
- Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Malignant Peritoneal Neoplasm” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.